Akoya Biosciences, Inc.
AKYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $82 | $97 | $75 | $55 |
| % Growth | -15.5% | 29.1% | 36.3% | – |
| Cost of Goods Sold | $34 | $40 | $31 | $21 |
| Gross Profit | $48 | $56 | $43 | $34 |
| % Margin | 58.6% | 58.3% | 58% | 62.3% |
| R&D Expenses | $20 | $22 | $23 | $16 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $69 | $82 | $80 | $51 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $6 | $10 | $7 | $5 |
| Operating Expenses | $95 | $114 | $110 | $71 |
| Operating Income | -$47 | -$58 | -$66 | -$37 |
| % Margin | -57.2% | -59.7% | -88.4% | -67.8% |
| Other Income/Exp. Net | -$8 | -$6 | -$4 | -$4 |
| Pre-Tax Income | -$55 | -$63 | -$71 | -$43 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$55 | -$63 | -$71 | -$43 |
| % Margin | -67.8% | -65.5% | -94.4% | -78.2% |
| EPS | -1.12 | -1.43 | -1.87 | -1.19 |
| % Growth | 21.7% | 23.5% | -57.1% | – |
| EPS Diluted | -1.12 | -1.43 | -1.87 | -1.19 |
| Weighted Avg Shares Out | 49 | 44 | 38 | 37 |
| Weighted Avg Shares Out Dil | 49 | 44 | 38 | 37 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $1 | $0 |
| Interest Expense | $10 | $9 | $5 | $3 |
| Depreciation & Amortization | $8 | $9 | $7 | $5 |
| EBITDA | -$37 | -$46 | -$59 | -$35 |
| % Margin | -45.5% | -47.2% | -78.6% | -64% |